AAPL 206.655 1.0044% MSFT 384.86 2.7965% NVDA 106.185 3.3833% GOOGL 158.72 2.1693% GOOG 160.73 1.9084% AMZN 185.5673 2.7504% META 530.91 2.0451% AVGO 187.43 5.9465% BRK-A 795500.0 0.8495% BRK-B 530.135 0.6312% LLY 855.05 3.0901% TSLA 255.535 1.9123% TSM 163.78 3.783% V 336.305 0.5787% JPM 243.935 1.2683% UNH 426.3 -0.3879% NVO 62.61 2.137% WMT 95.78 0.8635% LVMUY 113.69 1.6632% XOM 108.77 1.3039%
Last update at 2025-04-23T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 6048.96M | 1455.88M | 1370.94M | 4533.50M | 5036.43M |
| Minority interest | -38.54032M | -24.35455M | 305.08M | 291.76M | 289.81M |
| Net income | 4938.22M | 1215.68M | 1204.14M | 3747.73M | 4151.89M |
| Selling general administrative | 3211.61M | 2937.46M | 3066.21M | 3264.29M | 2902.22M |
| Selling and marketing expenses | 586.33M | 358.45M | 328.04M | 486.90M | 386.07M |
| Gross profit | 9621.30M | 4729.44M | 4684.76M | 8189.23M | 8280.00M |
| Reconciled depreciation | 1116.87M | 1179.92M | 1220.10M | 1223.30M | 1179.53M |
| Ebit | 6055.77M | 1634.00M | 1493.86M | 4678.96M | 5206.77M |
| Ebitda | 7172.65M | 2813.92M | 2713.96M | 5902.25M | 6386.30M |
| Depreciation and amortization | 1116.87M | 1179.92M | 1220.10M | 1223.30M | 1179.53M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 6007.06M | 1519.27M | 1373.04M | 4678.96M | 5206.77M |
| Other operating expenses | 14710.24M | 10882.79M | 10993.76M | 13951.37M | 13244.59M |
| Interest expense | 3.55M | 119.76M | 127.62M | 127.01M | 165.15M |
| Tax provision | 1072.19M | 215.85M | 149.68M | 773.19M | 880.20M |
| Interest income | 45.95M | 68.78M | 127.89M | 159.07M | 125.40M |
| Net interest income | 42.41M | -50.97142M | 0.27M | 32.05M | -39.75873M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 1072.19M | 215.85M | 149.68M | 773.19M | 880.20M |
| Total revenue | 20720.56M | 12460.42M | 12362.10M | 18474.31M | 18325.96M |
| Total operating expenses | 3610.98M | 3151.81M | 3316.42M | 3666.29M | 3198.62M |
| Cost of revenue | 11099.26M | 7730.98M | 7677.34M | 10285.08M | 10045.96M |
| Total other income expense net | -3.78064M | -70.77903M | 2.32M | -21.48810M | -5.18607M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 4976.76M | 1240.03M | 1221.25M | 3760.31M | 4156.23M |
| Net income applicable to common shares | 4938.22M | 1215.68M | 1204.14M | 3747.73M | 4151.89M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 29212.11M | 24258.81M | 20856.80M | 24221.67M | 26181.03M |
| Intangible assets | 610.48M | 648.59M | 719.99M | 715.03M | 771.57M |
| Earning assets | - | - | - | - | - |
| Other current assets | 168.77M | 26.47M | 225.53M | 40.72M | 51.33M |
| Total liab | 5114.32M | 4253.49M | 3238.87M | 5385.05M | 5915.90M |
| Total stockholder equity | 23801.13M | 19705.50M | 17286.12M | 18531.53M | 19973.37M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2441.74M | 2520.55M | 1564.81M | 1349.23M | 1903.16M |
| Common stock | 794.89M | 794.89M | 794.59M | 794.59M | 728.84M |
| Capital stock | 795.77M | 795.77M | 795.77M | 795.77M | 730.05M |
| Retained earnings | 22396.37M | 18355.23M | 15854.70M | 17143.53M | 18560.05M |
| Other liab | - | 798.82M | 900.77M | 893.22M | 763.81M |
| Good will | 60.57M | 60.75M | 71.02M | 63.82M | 66.77M |
| Other assets | - | 361.99M | 403.36M | 400.34M | 350.51M |
| Cash | 3774.05M | 2091.13M | 1802.03M | 1229.42M | 2080.58M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 4184.35M | 3414.97M | 2284.22M | 4418.03M | 2639.05M |
| Current deferred revenue | 803.18M | 2378.34M | 1299.54M | 1250.95M | - |
| Net debt | -3682.90960M | -2027.84487M | -1707.65190M | 1378.81M | 432.46M |
| Short term debt | 16.96M | 23.58M | 40.49M | 2534.43M | - |
| Short long term debt | - | - | - | 2497.29M | - |
| Short long term debt total | 91.14M | 63.28M | 94.37M | 2608.23M | 2513.04M |
| Other stockholder equity | 769.85M | 1539.71M | 1086.75M | 999.92M | 1181.98M |
| Property plant equipment | - | 11767.00M | 11598.79M | 11809.60M | 11860.08M |
| Total current assets | 15684.98M | 11418.78M | 8061.98M | 10800.91M | 11736.44M |
| Long term investments | 84.63M | 1.71M | 1.67M | 431.98M | 1395.66M |
| Net tangible assets | - | 18995.28M | 16493.93M | 17751.51M | 19133.81M |
| Short term investments | 6971.43M | 6185.04M | 4133.57M | 6908.69M | 6409.69M |
| Net receivables | 4408.47M | 2658.14M | 1461.05M | 2205.54M | 2747.66M |
| Long term debt | 24.22M | 24.15M | 23.22M | 20.83M | 2513.04M |
| Inventory | 362.26M | 325.74M | 327.56M | 309.20M | 330.32M |
| Accounts payable | 922.47M | 870.84M | 678.91M | 534.37M | 735.89M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -160.86097M | -215.35327M | 92.28M | 92.28M | 92.28M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 403.55M | 61.14M | 72.30M | 61.68M | 23.65M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 13527.13M | 12840.03M | 12794.83M | 13420.76M | 14444.59M |
| Capital lease obligations | 66.92M | 39.14M | 71.15M | 90.11M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -3222.52053M | 3136.70M | 460.83M | -1115.13122M | -679.92996M |
| Change to liabilities | 218.05M | 163.85M | -179.49830M | -65.10399M | 23.33M |
| Total cashflows from investing activities | -3222.52053M | 2252.06M | -363.85696M | -2854.50488M | -1430.59293M |
| Net borrowings | -42.59811M | -2544.27617M | -36.95885M | -168.29566M | -1000.00000M |
| Total cash from financing activities | -2656.11211M | -5255.44729M | -2736.97879M | -2475.94360M | -3245.33998M |
| Change to operating activities | 528.49M | -104.15441M | -267.42001M | -56.21567M | 110.37M |
| Net income | 6048.96M | 1455.88M | 1370.94M | 4533.50M | 5036.43M |
| Change in cash | 289.10M | 572.60M | -851.15710M | -442.16585M | 58.31M |
| Begin period cash flow | 1802.03M | 1229.42M | 2080.58M | 2522.75M | 2470.44M |
| End period cash flow | 2091.13M | 1802.03M | 1229.42M | 2080.58M | 2528.75M |
| Total cash from operating activities | 6212.62M | 3556.16M | 2260.53M | 4897.35M | 4733.93M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1116.87M | 1179.92M | 1220.10M | 1223.30M | 1179.53M |
| Other cashflows from investing activities | 43.77M | 82.23M | 160.71M | 139.61M | 139.92M |
| Dividends paid | -2542.65280M | -2544.86518M | -2543.96295M | -2150.89795M | 2042.69M |
| Change to inventory | -0.79976M | -18.45427M | 19.78M | 63.84M | -85.69556M |
| Change to account receivables | -1263.11470M | 670.86M | 525.33M | -254.16813M | -841.70176M |
| Sale purchase of stock | - | - | - | - | 0.00000M |
| Other cashflows from financing activities | -70.86119M | -166.30594M | -153.49507M | -156.75000M | -202.65000M |
| Change to netincome | 674.90M | 445.74M | -264.57920M | 235.44M | 192.37M |
| Capital expenditures | 1220.61M | 969.24M | 992.72M | 1885.19M | 893.44M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -463.35811M | 735.00M | 136.85M | -244.89134M | -748.23676M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -489.84980M | 185.36M | -467.36430M | -614.56310M | -733.79349M |
| Free cash flow | 4992.02M | 2586.92M | 1267.81M | 3012.16M | 3840.49M |
Sector: Healthcare Industry: Medical Care Facilities
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BUHPF Bumrungrad Hospital Public Company Limited |
- -% | 4.85 | 32.31 | 21.60 | 0.29 | 7.33 | 7.56 | 18.82 |
| HCA HCA Holdings Inc |
4.28 1.27% | 340.26 | 13.19 | 13.66 | 1.13 | 293.44 | 1.77 | 8.22 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.17 1.52% | 11.36 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| FSNUF Fresenius SE & Co. KGaA |
- -% | 37.73 | 16.76 | 9.62 | 0.42 | 0.79 | 0.78 | 5.31 |
| JDHIY JD Health International Inc |
- -% | 4.24 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. It operates allergy, arrhythmia, behavioral health, breast, home service, heart valve, robotic surgery, rehabilitation, children's, colorectal surgery, complex coronary artery intervention, cornea transplant, dental, diagnostic, dialysis, digestive disease, ear, nose, throat, emergency, endocrinology, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopedics, perinatal, plastic surgery, pulmonary, refractive surgery, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, comprehensive sleep, IVF, hearing and balance, medical, memory, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, vaccine clinics. In addition, it provides spine institute, diagnostic radiology and nuclear medicine, esperance, heart institute, intensive care unit, neurocritical care, nutrition services, pharmacy services, and preventive genomics and integrative medicine services. Further, the company offers clinical research; hospital consulting and management; healthcare personnel development and training; healthcare referral; and digital platform services. Additionally, it is involved in the distribution of pharmaceutical and medical goods in specialized stores; development of software for healthcare services; holding of real estate assets; and manufacture and sale of vitamin supplements. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand.
33 Sukhumvit Soi 3 (Nana Nua), Bangkok, Thailand, 10110
| Name | Title | Year Born |
|---|---|---|
| Ms. Linda Lisahapanya | Pres, MD & Exec. Director | 1953 |
| Ms. Artirat Charukitpipat | Chief Exec. Officer | 1968 |
| Ms. Oraphan Buamuang | Chief Financial Officer | 1974 |
| Ms. Supawan Sirinuntawit | Accounting Mang. | NA |
| Mr. Daniel Kastner | Chief Transformation Office & Head of IR | NA |
| Dr. Aniello M. Sorrentino Ph.D. | Corp. Chief Strategy Officer | 1947 |
| Mr. David T. Boucher FACHE | Chief Bus. Transformation Officer | NA |
| Tanee Maneenut | Chief Bus. Devel. Officer | NA |
| Ms. Rangsima Thongdee | Head of Internal Audit | NA |
| Jeremy Ford | Laboratory Research & Technology Director of Bumrungrad International Hospital | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...